Coeptis Therapeutics (NASDAQ:COEP) Trading Down 19.7% – Here’s What Happened

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) fell 19.7% during trading on Thursday . The stock traded as low as $10.49 and last traded at $10.61. 150,093 shares changed hands during mid-day trading, an increase of 163% from the average session volume of 57,040 shares. The stock had previously closed at $13.21.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Coeptis Therapeutics in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Coeptis Therapeutics Stock Down 19.7%

The company has a market cap of $56.66 million, a P/E ratio of -3.71 and a beta of -0.50. The stock has a 50-day moving average of $14.55 and a two-hundred day moving average of $14.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.21 and a current ratio of 2.21.

Coeptis Therapeutics (NASDAQ:COEP) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.58) EPS for the quarter. The business had revenue of $0.24 million for the quarter.

Institutional Investors Weigh In On Coeptis Therapeutics

A hedge fund recently bought a new stake in Coeptis Therapeutics stock. Yorkville Advisors Global LP bought a new stake in shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 8,000 shares of the company’s stock, valued at approximately $140,000. Coeptis Therapeutics accounts for 0.0% of Yorkville Advisors Global LP’s portfolio, making the stock its 24th biggest holding. Yorkville Advisors Global LP owned 0.17% of Coeptis Therapeutics as of its most recent filing with the Securities and Exchange Commission. 13.88% of the stock is currently owned by institutional investors.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.